Meeder Asset Management Inc. increased its position in West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 39.9% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 15,260 shares of the medical instruments supplier’s stock after purchasing an additional 4,349 shares during the quarter. Meeder Asset Management Inc.’s holdings in West Pharmaceutical Services were worth $5,658,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds also recently made changes to their positions in WST. BlackRock Inc. purchased a new position in West Pharmaceutical Services during the second quarter valued at $2,387,990,000. Bank of New York Mellon Corp bought a new stake in shares of West Pharmaceutical Services during the 2nd quarter valued at $733,733,000. Generation Investment Management LLP purchased a new stake in shares of West Pharmaceutical Services in the 2nd quarter worth about $728,168,000. Aberdeen Group plc grew its position in shares of West Pharmaceutical Services by 2,283.1% in the 3rd quarter. Aberdeen Group plc now owns 1,462,033 shares of the medical instruments supplier’s stock worth $542,063,000 after buying an additional 1,400,682 shares during the period. Finally, Findlay Park Partners LLP purchased a new stake in shares of West Pharmaceutical Services in the 2nd quarter worth about $214,196,000. 93.90% of the stock is currently owned by institutional investors.
Insider Activity at West Pharmaceutical Services
In other news, VP Annette Favorite sold 2,524 shares of the stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $365.00, for a total transaction of $921,260.00. Following the sale, the vice president owned 21,818 shares in the company, valued at $7,963,570. This represents a 10.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 15,659 shares of company stock worth $5,443,749 in the last 90 days. Corporate insiders own 0.60% of the company’s stock.
Wall Street Analysts Forecast Growth
Several research analysts recently issued reports on the stock. Weiss Ratings upgraded shares of West Pharmaceutical Services from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, November 2nd. Citigroup lifted their price target on shares of West Pharmaceutical Services from $412.00 to $494.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Evercore reissued an “outperform” rating and set a $425.00 price objective on shares of West Pharmaceutical Services in a research note on Monday, July 27th. Jefferies Financial Group restated a “buy” rating and issued a $475.00 price objective on shares of West Pharmaceutical Services in a report on Monday, November 2nd. Finally, Zacks Research downgraded shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 12th. Thirteen investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $424.67.
Check Out Our Latest Stock Analysis on West Pharmaceutical Services
West Pharmaceutical Services Stock Performance
Shares of West Pharmaceutical Services stock opened at $404.61 on Thursday. The stock has a market cap of $28.19 billion, a price-to-earnings ratio of 45.41, a PEG ratio of 2.52 and a beta of 1.13. The firm’s 50-day moving average is $384.73 and its 200 day moving average is $323.52. West Pharmaceutical Services, Inc. has a 1 year low of $223.83 and a 1 year high of $438.27. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.10.
West Pharmaceutical Services (NYSE:WST – Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The medical instruments supplier reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.20 by $0.46. The business had revenue of $874.50 million during the quarter, compared to analyst estimates of $827.12 million. West Pharmaceutical Services had a net margin of 18.81% and a return on equity of 21.78%. West Pharmaceutical Services’s revenue was up 8.7% compared to the same quarter last year. During the same period last year, the business earned $1.96 EPS. Sell-side analysts anticipate that West Pharmaceutical Services, Inc. will post 9.45 EPS for the current fiscal year.
West Pharmaceutical Services Increases Dividend
The company also recently announced a quarterly dividend, which was paid on Wednesday, November 18th. Stockholders of record on Wednesday, November 11th were paid a $0.26 dividend. This is a boost from West Pharmaceutical Services’s previous quarterly dividend of $0.22. This represents a $1.04 annualized dividend and a dividend yield of 0.3%. The ex-dividend date was Tuesday, November 10th. West Pharmaceutical Services’s payout ratio is currently 11.67%.
About West Pharmaceutical Services
West Pharmaceutical Services designs and manufactures packaging components and delivery systems used by the pharmaceutical, biotechnology, and medical device industries. Its products help contain and administer injectable medicines and include elastomeric components, such as stoppers and seals, as well as syringe components and other packaging and delivery solutions. The company also provides contract manufacturing services for medical devices and pharmaceutical delivery systems. Its customers include companies developing and producing branded, generic, and biologic medicines.
Featured Articles
- Five stocks we like better than West Pharmaceutical Services
- From Berlin to Brussels: Tesla’s $3.3 Billion Robotaxi Gamble
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST – Free Report).
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.
